Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Project cooperationUpdated on 9 April 2026

ASP210

Filip Rázga

CEO at Selecta Biotech SE

Bratislava, Slovakia

About

ASP210 is a therapeutic oligonucleotide leveraging the ESiNAR-X platform to target BCR-ABL1 mRNA in patients with chronic myeloid leukemia who are resistant or refractory to TKI therapy.

Status: Finished pre-clinical validation

We are seeking investments and partnerships to support the execution of clinical trials.

Similar opportunities